巴雷特食管瘤变内镜治疗成功后复发肠化生和异型增生率:内镜黏膜切除与内镜黏膜下剥离联合消融术的大规模北美多中心队列研究
该多中心队列纳入3家学术机构中经内镜根除治疗达到完全缓解肠化生的621例巴雷特食管患者(内镜黏膜切除514例,内镜黏膜下剥离107例),比较两种切除技术联合消融后的复发率。结果显示两组任何巴雷特食管复发率(每100患者年15.7 vs 5.7)和异型增生巴雷特食管复发率(每100患者年7.3 vs 5.3)相当,多因素分析中切除技术不影响复发风险(风险比0.87,95%置信区间0.51-1.49,P=0.62),逆概率治疗加权分析证实(风险比0.98,95%置信区间0.56-1.73,P=0.94)。
要点
- 内镜黏膜切除联合消融与内镜黏膜下剥离联合消融达到完全缓解肠化生后,巴雷特食管复发率相当。
- 多因素分析显示切除技术不是巴雷特食管复发的独立预测因素(风险比0.87,95%置信区间0.51-1.49,P=0.62)。
- 巴雷特食管长度、病变大小和吸烟史是巴雷特食管复发的独立预测因素。
核心结论
- 达到完全缓解肠化生的巴雷特食管异型增生/瘤变患者,初始内镜黏膜切除联合消融与内镜黏膜下剥离联合消融的复发率相当。
- 作者认为需要随机试验来确认两种内镜切除技术之间的这些结果。
研究设计与样本
- 多中心队列研究,纳入3家学术机构中接受内镜根除治疗并达到完全缓解肠化生的患者。
- 复发分析共纳入621例患者,其中内镜黏膜切除514例,内镜黏膜下剥离107例。
- 采用Cox比例风险模型和逆概率治疗加权分析。
主要发现
- 内镜黏膜切除组任何巴雷特食管复发率为每100患者年15.7,内镜黏膜下剥离组为每100患者年5.7,两组相当。
- 内镜黏膜切除组异型增生巴雷特食管复发率为每100患者年7.3,内镜黏膜下剥离组为每100患者年5.3,两组相当。
- 多因素分析中,内镜切除技术不影响巴雷特食管复发风险(风险比0.87;95%置信区间0.51-1.49;P=0.62)。
- 逆概率治疗加权分析证实内镜黏膜下剥离与内镜黏膜切除相比,风险比0.98;95%置信区间0.56-1.73;P=0.94。
- 巴雷特食管长度、病变大小和吸烟史是巴雷特食管复发的独立预测因素。
局限性
- 作者指出需要随机试验来确认两种内镜切除技术之间的这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endoscopic eradication therapy (EET) combining endoscopic resection (ER) with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) followed by ablation is the standard of care for the treatment of dysplastic Barrett's esophagus (BE). We have previously shown comparable rates of complete remission of intestinal metaplasia (CRIM) with both approaches. However, data comparing recurrence after CRIM are lacking. We compared rates of recurrence after CRIM with both techniques in a multicenter cohort. METHODS: Patients undergoing EET achieving CRIM at 3 academic institutions were included. Demographic and clinical data were abstracted. Outcomes included rates and predictors of any BE and dysplastic BE recurrence in the 2 groups. Cox-proportional hazards models and inverse probability treatment weighting (IPTW) analysis were used for analysis. RESULTS: A total of 621 patients (514 EMR and 107 ESD) achieving CRIM were included in the recurrence analysis. The incidence of any BE (15.7, 5.7 per 100 patient-years) and dysplastic BE recurrence (7.3, 5.3 per 100 patient-years) were comparable in the EMR and ESD groups, respectively. On multivariable analyses, the chances of BE recurrence were not influenced by ER technique (hazard ratio 0.87; 95% confidence interval 0.51-1.49; P = 0.62), which was also confirmed by IPTW analysis (ESD vs EMR: hazard ratio 0.98; 95% confidence interval 0.56-1.73; P = 0.94). BE length, lesion size, and history of cigarette smoking were independent predictors of BE recurrence. DISCUSSION: Patients with BE dysplasia/neoplasia achieving CRIM, initially treated with EMR/ablation, had comparable recurrence rates to ESD/ablation. Randomized trials are needed to confirm these outcomes between the 2 ER techniques.
引用
- Vantanasiri K, Joseph A, Sachdeva K, et al. Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection and Ablation: A Large North American Multicenter Cohort. Am J Gastroenterol. 2024. PMID: 38587280. doi:10.14309/ajg.0000000000002798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。